Download MendeleyOptimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4.
Guo, J., Chen, X., Li, X., Wang, X., Shao, M., Song, X., Zhang, L., Huang, S., Patterson, A.V., Smaill, J.B., Zhou, Y., Yu, X., Chen, Y., Lu, X.(2025) Bioorg Chem 160: 108469-108469
- PubMed: 40252369 Search on PubMed
- DOI: https://doi.org/10.1016/j.bioorg.2025.108469
- Primary Citation Related Structures:
9K0I, 9K0J - PubMed Abstract:
The Fibroblast growth factor receptor 4 (FGFR4) has emerged as a potential oncogenic driver in hepatocellular carcinoma (HCC), primarily due to aberrations in the FGFR4-FGF19 signaling axis. Although the FGFR4-selective inhibitors have been reported, none have received approval. Further, the clinical acquired resistance caused by FGFR4 mutations has become an unmet clinical need for cancer therapy. In this study, we designed and synthesized a series of 3-amido-1H-indazole-based FGFR4 irreversible inhibitors, targeting both wild-type FGFR4 and the gatekeeper and molecular brake mutants. The representative compound, 48c, exhibited potent inhibitory activity against FGFR4 WT kinase (IC 50 = 2.9 nM) and picomolar activity against FGFR4 WT , FGFR4 V550L , and FGFR4 V550M -driven Ba/F3 cell lines (IC 50 < 0.1, 0.3, and 0.3 nM, respectively). 48c exhibited high selectivity across a panel of 66 kinases harboring a cysteine at the hinge region, highlighting its potential as a promising therapeutic candidate for overcoming resistance in FGFR4-associated tumors.
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou 510632, China.
Organizational Affiliation:
